Vihang Nakhate
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vihang Nakhate has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Gilbert Youssef
Harvard Medical School , Boston, Massachusetts
5 shared publications - Aleksandra B. Lasica
Harvard Medical School , Boston, Massachusetts
4 shared publications - Elisa Aquilanti
Harvard Medical School , Boston, Massachusetts
4 shared publications - Lakshmi Nayak
Harvard Medical School , Boston, Massachusetts
4 shared publications Tracy T Batchelor
Center for Tumors of the Nervous System and Pappas Center for Neuro-Oncology, Mass General Brigham Cancer Institute , Boston, Massachusetts
4 shared publications- Ugonma Chukwueke
Harvard Medical School , Boston, Massachusetts
4 shared publications
Latest Publications
- 5 November 2026
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 39 (6) , 586-596
The blood–brain barrier and strategies for drug delivery to brain tumors
Purpose of review: Drug delivery across the blood–brain barrier (BBB) remains an important challenge in the treatment of brain tumors. This review summarizes the physiologic barriers to effective CNS drug exposure and evaluates strategies to improve delivery, with a focus on glioma. Recent findings: Recent advances span three complementary approaches: engineering therapeutics for BBB penetration, transient BBB disruption, and locoregional delivery to bypass the BBB. Modern medicinal chemistry has enabled highly brain-penetrant agents such as vorasidenib, while transporter/receptor-mediated and nanocarrier platforms remain under investigation. Ultrasound with microbubbles has emerged as a leading strategy for spatially targeted, reversible BBB disruption, with early clinical studies demonstrating increased delivery of chemotherapies and monoclonal antibodies. Convection-enhanced delivery has benefited from improved catheter design, image guidance, and implantable systems, although efficacy in brain tumors remains unproven. Intratumoral oncolytic viruses and CSF-based cellular therapies are additional emerging approaches. Summary: Strategies for drug delivery to brain tumors have advanced substantially, but translation remains challenging. Efficacious therapies must not only overcome the BBB but also achieve adequate exposure and target engagement across heterogeneous tumor regions. Future studies must pair active therapeutics with relevant delivery strategies, ascertain drug exposure and target engagement early through window-of-opportunity studies, and evaluate efficacy in randomized trials.
- 5 November 2026
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 39 (6) , 586-596
The blood–brain barrier and strategies for drug delivery to brain tumors
Purpose of review: Drug delivery across the blood–brain barrier (BBB) remains an important challenge in the treatment of brain tumors. This review summarizes the physiologic barriers to effective CNS drug exposure and evaluates strategies to improve delivery, with a focus on glioma. Recent findings: Recent advances span three complementary approaches: engineering therapeutics for BBB penetration, transient BBB disruption, and locoregional delivery to bypass the BBB. Modern medicinal chemistry has enabled highly brain-penetrant agents such as vorasidenib, while transporter/receptor-mediated and nanocarrier platforms remain under investigation. Ultrasound with microbubbles has emerged as a leading strategy for spatially targeted, reversible BBB disruption, with early clinical studies demonstrating increased delivery of chemotherapies and monoclonal antibodies. Convection-enhanced delivery has benefited from improved catheter design, image guidance, and implantable systems, although efficacy in brain tumors remains unproven. Intratumoral oncolytic viruses and CSF-based cellular therapies are additional emerging approaches. Summary: Strategies for drug delivery to brain tumors have advanced substantially, but translation remains challenging. Efficacious therapies must not only overcome the BBB but also achieve adequate exposure and target engagement across heterogeneous tumor regions. Future studies must pair active therapeutics with relevant delivery strategies, ascertain drug exposure and target engagement early through window-of-opportunity studies, and evaluate efficacy in randomized trials.
- 16 October 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Prognostic significance of contrast enhancement in newly diagnosed grade 2 IDH-mutant glioma
Background: Contrast enhancement is generally considered an adverse prognostic feature in adult glioma. However, its significance in newly diagnosed grade 2 isocitrate dehydrogenase (IDH)-mutant glioma remains uncertain, with important implications for use of the mutant IDH inhibitor vorasidenib. We evaluated survival outcomes associated with preoperative enhancement in this population. Methods: We retrospectively evaluated consecutive patients with grade 2 IDH-mutant glioma treated at 2 institutions between 2010 and 2021. Preoperative MRIs were assessed for intratumoral enhancement by 2 independent readers with third-reader adjudication. Overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier analysis and univariate and multivariable Cox regression. Results: Among 325 evaluable patients, the median age was 37 years, 47% had 1p/19q-codeletion, and 35% had gross total resection. Median follow-up was 10.5 years. Preoperative enhancement was observed in 53 (16%) patients, most commonly nonmeasurable (72%) or ill-defined (62%); most (87%) had no residual postoperative enhancement. Preoperative enhancement was not associated with OS or PFS in either univariate analyses (OS hazard ratio [HR] 1.16 [0.67-2.01], P = .591; PFS HR 1.25 [0.88-1.80], P = .216) or multivariable analyses adjusting for established prognostic factors (OS HR 0.86 [0.46-1.61], P = .633; PFS HR 1.29 [0.86-1.92], P = .219). Enhancement characteristics (measurable size, well-defined morphology) were not associated with OS. Conclusions: In grade 2 IDH-mutant glioma, preoperative enhancement was not associated with OS or PFS. These findings suggest that preoperative enhancement does not identify a higher-risk subgroup in this population and that its presence alone should not preclude consideration of vorasidenib in eligible patients.
- 16 October 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Prognostic significance of contrast enhancement in newly diagnosed grade 2 IDH-mutant glioma
Background: Contrast enhancement is generally considered an adverse prognostic feature in adult glioma. However, its significance in newly diagnosed grade 2 isocitrate dehydrogenase (IDH)-mutant glioma remains uncertain, with important implications for use of the mutant IDH inhibitor vorasidenib. We evaluated survival outcomes associated with preoperative enhancement in this population. Methods: We retrospectively evaluated consecutive patients with grade 2 IDH-mutant glioma treated at 2 institutions between 2010 and 2021. Preoperative MRIs were assessed for intratumoral enhancement by 2 independent readers with third-reader adjudication. Overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier analysis and univariate and multivariable Cox regression. Results: Among 325 evaluable patients, the median age was 37 years, 47% had 1p/19q-codeletion, and 35% had gross total resection. Median follow-up was 10.5 years. Preoperative enhancement was observed in 53 (16%) patients, most commonly nonmeasurable (72%) or ill-defined (62%); most (87%) had no residual postoperative enhancement. Preoperative enhancement was not associated with OS or PFS in either univariate analyses (OS hazard ratio [HR] 1.16 [0.67-2.01], P = .591; PFS HR 1.25 [0.88-1.80], P = .216) or multivariable analyses adjusting for established prognostic factors (OS HR 0.86 [0.46-1.61], P = .633; PFS HR 1.29 [0.86-1.92], P = .219). Enhancement characteristics (measurable size, well-defined morphology) were not associated with OS. Conclusions: In grade 2 IDH-mutant glioma, preoperative enhancement was not associated with OS or PFS. These findings suggest that preoperative enhancement does not identify a higher-risk subgroup in this population and that its presence alone should not preclude consideration of vorasidenib in eligible patients.
- Open Access
- 4 May 2026
- Published by Elsevier in Neurotherapeutics
- Vol. 23 (6) , e00913
Current and emerging therapies in IDH-mutant glioma
- 4 May 2026
- Published by Elsevier in Neurotherapeutics
- Vol. 23 (6) , e00913
Open AccessCurrent and emerging therapies in IDH-mutant glioma
- 15 December 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (3) , 752-764
Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma
Background: The prognostic and predictive value of O6-methylguanine-DNA methyltransferase promoter (MGMTp) methylation is not well established in isocitrate dehydrogenase (IDH)-mutant gliomas. This study evaluates the survival impact of MGMTp and other clinical, molecular, and radiologic variables in low-grade and high-grade IDH-mutant gliomas. Methods: We retrospectively evaluated 520 consecutive adult patients treated for an initial diagnosis of IDH-mutant glioma, of any histological grade, at two large academic institutions. MGMTp methylation was evaluated by methylation-specific polymerase chain reaction (PCR) analysis. Log-rank test and Cox proportional hazards model were applied to evaluate the association of clinical, molecular, and radiological characteristics with overall survival (OS) and progression-free survival (PFS). Results: Median age was 36.6 years; MGMTp was methylated in 70% and unmethylated in 30%. MGMTp methylation was not significantly associated with OS (P = 0.11) or PFS (P = 0.74) on multivariate analyses. Cyclin dependent kinase inhibitor 2A/B (CDKN2A/B) homozygous deletion [HR = 3.26 (1.47, 7.23), P = .006] and an integrated grade 4 classification [HR = 2.08 (1.06, 4.67), P = .048] were strong predictors of OS in astrocytoma, whereas maximal resection [HR = 0.06 (0.01, 0.57), p = 0.016] and radiation [HR = 0.41 (0.18, 0.91), P = .03] were strong prognosticators for PFS in the entire cohort. Maximal resection of the enhancing disease [HR = 0.17 (0.05, 0.96), P = .014] and radiation [HR = 0.47 (0.19, 0.65), P = .046] were strongly associated with PFS in grade 2 and 3 gliomas. Conclusion: MGMTp methylation was not associated with a prognostic or predictive value in our IDH-mutant glioma cohort. CDKN2A/B status and extent of resection were strong predictors of outcomes.
- 15 December 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (3) , 752-764
Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma
Background: The prognostic and predictive value of O6-methylguanine-DNA methyltransferase promoter (MGMTp) methylation is not well established in isocitrate dehydrogenase (IDH)-mutant gliomas. This study evaluates the survival impact of MGMTp and other clinical, molecular, and radiologic variables in low-grade and high-grade IDH-mutant gliomas. Methods: We retrospectively evaluated 520 consecutive adult patients treated for an initial diagnosis of IDH-mutant glioma, of any histological grade, at two large academic institutions. MGMTp methylation was evaluated by methylation-specific polymerase chain reaction (PCR) analysis. Log-rank test and Cox proportional hazards model were applied to evaluate the association of clinical, molecular, and radiological characteristics with overall survival (OS) and progression-free survival (PFS). Results: Median age was 36.6 years; MGMTp was methylated in 70% and unmethylated in 30%. MGMTp methylation was not significantly associated with OS (P = 0.11) or PFS (P = 0.74) on multivariate analyses. Cyclin dependent kinase inhibitor 2A/B (CDKN2A/B) homozygous deletion [HR = 3.26 (1.47, 7.23), P = .006] and an integrated grade 4 classification [HR = 2.08 (1.06, 4.67), P = .048] were strong predictors of OS in astrocytoma, whereas maximal resection [HR = 0.06 (0.01, 0.57), p = 0.016] and radiation [HR = 0.41 (0.18, 0.91), P = .03] were strong prognosticators for PFS in the entire cohort. Maximal resection of the enhancing disease [HR = 0.17 (0.05, 0.96), P = .014] and radiation [HR = 0.47 (0.19, 0.65), P = .046] were strongly associated with PFS in grade 2 and 3 gliomas. Conclusion: MGMTp methylation was not associated with a prognostic or predictive value in our IDH-mutant glioma cohort. CDKN2A/B status and extent of resection were strong predictors of outcomes.
- Open Access
- 8 December 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitors
Background: Sex differences in glioblastoma (GBM) are recognized, but their treatment implications remain unclear. Recent preclinical studies have characterized mechanisms of sex-biased anti-tumor immunity in GBM, and have found in murine models that males derive greater survival benefit from immune checkpoint inhibitor (ICI). We evaluated sex differences associated with ICI in GBM patients. Methods: We retrospectively evaluated consecutive patients with newly diagnosed GBM (nGBM) or recurrent GBM (rGBM) treated with ICI on clinical trials at one institution from 2014 to 2022. Progression-free survival (PFS) and overall survival (OS) were evaluated by Kaplan-Meier analysis, univariate and multivariable regression models. Sex-by-treatment interactions were assessed relative to a concurrent reference group treated on non-ICI clinical trials. Results: 296 patients with nGBM (58% male, 19% ICI) and 458 patients with rGBM (60% male, 40% ICI) were evaluated. In nGBM, ICI was not associated with sex difference in PFS (HRmale 1.35; 95% CI, 0.62–2.95; P = .446; Pinteraction = .142) or OS (HRmale 1.15 [0.53–2.53], P = .722; Pinteraction = .438) compared to non-ICI treatment. In rGBM, males receiving ICI had worse OS (HRmale 1.64 [1.09–2.47], P = .017) and trended towards worse PFS (HRmale 1.41 [0.94–2.11], P = .095), but sex differences with ICI were not significantly different compared to non-ICI treatment (PFS Pinteraction = .610; OS Pinteraction = .361). No sex differences were observed when all immunotherapies were analyzed collectively. Conclusion: In nGBM and rGBM, ICI therapy was not associated with sex difference in PFS or OS. Clinically meaningful sex-based outcome differences may be better understood by prospective evaluation in clinical trials.
- 8 December 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Open AccessEvaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitors
Background: Sex differences in glioblastoma (GBM) are recognized, but their treatment implications remain unclear. Recent preclinical studies have characterized mechanisms of sex-biased anti-tumor immunity in GBM, and have found in murine models that males derive greater survival benefit from immune checkpoint inhibitor (ICI). We evaluated sex differences associated with ICI in GBM patients. Methods: We retrospectively evaluated consecutive patients with newly diagnosed GBM (nGBM) or recurrent GBM (rGBM) treated with ICI on clinical trials at one institution from 2014 to 2022. Progression-free survival (PFS) and overall survival (OS) were evaluated by Kaplan-Meier analysis, univariate and multivariable regression models. Sex-by-treatment interactions were assessed relative to a concurrent reference group treated on non-ICI clinical trials. Results: 296 patients with nGBM (58% male, 19% ICI) and 458 patients with rGBM (60% male, 40% ICI) were evaluated. In nGBM, ICI was not associated with sex difference in PFS (HRmale 1.35; 95% CI, 0.62–2.95; P = .446; Pinteraction = .142) or OS (HRmale 1.15 [0.53–2.53], P = .722; Pinteraction = .438) compared to non-ICI treatment. In rGBM, males receiving ICI had worse OS (HRmale 1.64 [1.09–2.47], P = .017) and trended towards worse PFS (HRmale 1.41 [0.94–2.11], P = .095), but sex differences with ICI were not significantly different compared to non-ICI treatment (PFS Pinteraction = .610; OS Pinteraction = .361). No sex differences were observed when all immunotherapies were analyzed collectively. Conclusion: In nGBM and rGBM, ICI therapy was not associated with sex difference in PFS or OS. Clinically meaningful sex-based outcome differences may be better understood by prospective evaluation in clinical trials.
- 29 May 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (9) , 2382-2398
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4
Background: Astrocytoma, isocitrate dehydrogenase-mutant, WHO grade 4 (Astro4), is a new tumor type in the 2021 WHO classification of central nervous system tumors that has been poorly characterized in the literature. This study evaluates predictors of prognosis in a large cohort of newly diagnosed Astro4. Methods: We retrospectively identified 128 consecutive adult patients who presented with an initial diagnosis of Astro4 at Dana-Farber Cancer Institute and Massachusetts General Hospital between 2010 and 2021. Clinical, molecular, and radiological characteristics were recorded, and their associations with overall survival (OS) and progression-free survival (PFS) were measured by log-rank test and Cox proportional hazards model. Results: The median age at diagnosis was 37.1 years, and 61.7% were men. The median OS was 5.9 years (95% confidence interval, 4.4–7.3), while the median PFS was 2.7 years (1.8 –3.6). Age ≥ 50 and homozygous CDKN2A/B deletion were independent negative prognosticators of OS on univariate and multivariate analyses (hazard ratio [HR], 2.21 [1.16–4.21], P = .019; HR, 2.61 [1.27–5.38], P = .013). Maximal resection of enhancing disease was associated with longer PFS on univariate and multivariate analyses (HR, 0.48 [0.26–0.87], P = .019). There were no significant differences in OS or PFS based on MGMT promoter methylation status, T2/FLAIR extent of resection, T2/FLAIR mismatch, radiological pseudoprogression, or enhancement on the pre-operative scan. Conclusions: Our study comprehensively characterizes a large cohort of newly diagnosed patients with Astro4, emphasizing the prognostic value of CDKN2A/B deletion, age, and the extent of resection of enhancing disease in these patients.
- 29 May 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (9) , 2382-2398
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4
Background: Astrocytoma, isocitrate dehydrogenase-mutant, WHO grade 4 (Astro4), is a new tumor type in the 2021 WHO classification of central nervous system tumors that has been poorly characterized in the literature. This study evaluates predictors of prognosis in a large cohort of newly diagnosed Astro4. Methods: We retrospectively identified 128 consecutive adult patients who presented with an initial diagnosis of Astro4 at Dana-Farber Cancer Institute and Massachusetts General Hospital between 2010 and 2021. Clinical, molecular, and radiological characteristics were recorded, and their associations with overall survival (OS) and progression-free survival (PFS) were measured by log-rank test and Cox proportional hazards model. Results: The median age at diagnosis was 37.1 years, and 61.7% were men. The median OS was 5.9 years (95% confidence interval, 4.4–7.3), while the median PFS was 2.7 years (1.8 –3.6). Age ≥ 50 and homozygous CDKN2A/B deletion were independent negative prognosticators of OS on univariate and multivariate analyses (hazard ratio [HR], 2.21 [1.16–4.21], P = .019; HR, 2.61 [1.27–5.38], P = .013). Maximal resection of enhancing disease was associated with longer PFS on univariate and multivariate analyses (HR, 0.48 [0.26–0.87], P = .019). There were no significant differences in OS or PFS based on MGMT promoter methylation status, T2/FLAIR extent of resection, T2/FLAIR mismatch, radiological pseudoprogression, or enhancement on the pre-operative scan. Conclusions: Our study comprehensively characterizes a large cohort of newly diagnosed patients with Astro4, emphasizing the prognostic value of CDKN2A/B deletion, age, and the extent of resection of enhancing disease in these patients.
- 8 January 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 12 (3) , 426-436
A pilot study to quantify and describe personal social networks in patients with glioblastoma
Background: Patients with glioblastoma experience high physical and psychosocial symptom burden. Poor social relationships have been shown to increase the risk of neurologic illnesses and decline, and conversely, strong personal social networks (PSN) have been shown to reduce the risk of mortality and improve quality of life. The aim of this pilot study is to determine the feasibility of measuring PSN in glioblastoma patients. Methods: We recruited 25 adult glioblastoma patients between the initial diagnosis and the first cycle of adjuvant chemotherapy from March to September 2023 in the outpatient neuro-oncology clinic and adapted PERSNET, a quantitative PSN assessment tool, to this population. We collected demographics, tumor measures, treatment courses, and the European Organization for Research and Treatment of Cancer QOL for Patients with Brain Tumors (EORTC QLQ-BN20) and conducted qualitative interviews. Results: The average age was 64.5 years old, 56% were female, and 84% had a Karnofsky Performance Status of 70 or higher. Patients had large network sizes (total size of patient’s PSN; mean = 8.8). Participants stressed the importance of social support and how different people filled different roles in their oncology care. Behavioral and/or cognitive changes resulted in delayed presentation, and children, especially daughters, were important in advocating for presentation to the hospital. Conclusion: This is the first proof-of-concept study showing that PSN can be measured in patients with glioblastoma. Qualitative data showed that patients felt social support was very important, and different people in their networks addressed different domains of care: physical, emotional, and logistical.
- 8 January 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 12 (3) , 426-436
A pilot study to quantify and describe personal social networks in patients with glioblastoma
Background: Patients with glioblastoma experience high physical and psychosocial symptom burden. Poor social relationships have been shown to increase the risk of neurologic illnesses and decline, and conversely, strong personal social networks (PSN) have been shown to reduce the risk of mortality and improve quality of life. The aim of this pilot study is to determine the feasibility of measuring PSN in glioblastoma patients. Methods: We recruited 25 adult glioblastoma patients between the initial diagnosis and the first cycle of adjuvant chemotherapy from March to September 2023 in the outpatient neuro-oncology clinic and adapted PERSNET, a quantitative PSN assessment tool, to this population. We collected demographics, tumor measures, treatment courses, and the European Organization for Research and Treatment of Cancer QOL for Patients with Brain Tumors (EORTC QLQ-BN20) and conducted qualitative interviews. Results: The average age was 64.5 years old, 56% were female, and 84% had a Karnofsky Performance Status of 70 or higher. Patients had large network sizes (total size of patient’s PSN; mean = 8.8). Participants stressed the importance of social support and how different people filled different roles in their oncology care. Behavioral and/or cognitive changes resulted in delayed presentation, and children, especially daughters, were important in advocating for presentation to the hospital. Conclusion: This is the first proof-of-concept study showing that PSN can be measured in patients with glioblastoma. Qualitative data showed that patients felt social support was very important, and different people in their networks addressed different domains of care: physical, emotional, and logistical.
- 20 September 2024
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 24 (12) , 631-643
The Role of Mutant IDH Inhibitors in the Treatment of Glioma
Purpose of Review The identification of isocitrate dehydrogenase (IDH) mutations has led to a transformation in our understanding of gliomas and has paved the way to a new era of targeted therapy. In this article, we review the classification of IDH-mutant glioma, standard of care treatment options, clinical evidence for mutant IDH (mIDH) inhibitors, and practical implications of the recent landmark INDIGO trial. Recent Findings In the phase 3 randomized placebo-controlled INDIGO trial, mIDH1/2 inhibitor vorasidenib increased progression-free survival among non-enhancing grade 2 IDH-mutant gliomas following surgery. This marks the first positive randomized trial of targeted therapy in IDH-mutant glioma, and led to the US Food and Drug Administration’s approval of vorasidenib in August 2024 for grade 2 IDH-mutant glioma. Summary Vorasidenib is a well-tolerated treatment that can benefit a subset of patients with IDH-mutant glioma. Targeting mIDH also remains a promising strategy for select groups of patients excluded from the INDIGO trial. Ongoing and future studies, including with new agents and with combination therapy approaches, may expand the benefit and unlock the potential of mIDH inhibitors.
- 20 September 2024
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 24 (12) , 631-643
The Role of Mutant IDH Inhibitors in the Treatment of Glioma
Purpose of Review The identification of isocitrate dehydrogenase (IDH) mutations has led to a transformation in our understanding of gliomas and has paved the way to a new era of targeted therapy. In this article, we review the classification of IDH-mutant glioma, standard of care treatment options, clinical evidence for mutant IDH (mIDH) inhibitors, and practical implications of the recent landmark INDIGO trial. Recent Findings In the phase 3 randomized placebo-controlled INDIGO trial, mIDH1/2 inhibitor vorasidenib increased progression-free survival among non-enhancing grade 2 IDH-mutant gliomas following surgery. This marks the first positive randomized trial of targeted therapy in IDH-mutant glioma, and led to the US Food and Drug Administration’s approval of vorasidenib in August 2024 for grade 2 IDH-mutant glioma. Summary Vorasidenib is a well-tolerated treatment that can benefit a subset of patients with IDH-mutant glioma. Targeting mIDH also remains a promising strategy for select groups of patients excluded from the INDIGO trial. Ongoing and future studies, including with new agents and with combination therapy approaches, may expand the benefit and unlock the potential of mIDH inhibitors.
- 8 May 2023
- Published by SAGE Publications in The Neurohospitalist
- Vol. 13 (4) , 399-402
Subacute Brachial Plexopathy due to Intraneural Epithelioid Hemangioma: A Case Report
Brachial plexopathy is a common consideration in the differential diagnosis of upper extremity sensory and motor deficits, and neoplasms signify one possible etiology of brachial plexopathy. Of the neoplastic brachial plexopathies, hemangiomas involving the brachial plexus are rare. Most reported cases describe extraneural brachial plexus hemangiomas that present as a palpable, tender neck mass associated with pain and sensory disturbance, with minimal motor deficits. Here we share the case of a 48 year-old man with intraneural epithelioid hemangioma of the brachial plexus who presented with prominent motor weakness and no palpable mass. The patient presented with subacute onset of left arm pain, numbness and progressive weakness. Neurologic exam revealed lower motor neuron signs and weakness spanning multiple nerve root and peripheral nerve distributions. Dedicated brachial plexus MRI showed two mass lesions involving the cords of the brachial plexus, with corresponding FDG-avidity on PET/CT. Biopsy revealed intraneural atypical epithelioid hemangioma. After nerve transfer surgery, he had moderate improvement in left arm strength. This case serves to: emphasize the importance of both clinical localization and dedicated brachial plexus imaging in the evaluation of brachial plexopathy; introduce to the literature a new clinical presentation of brachial plexus hemangiomas; encourage consideration of neoplastic brachial plexopathy even when faced with an illness script resembling Parsonage-Turner Syndrome, to avoid delays in diagnosis and treatment.
- 8 May 2023
- Published by SAGE Publications in The Neurohospitalist
- Vol. 13 (4) , 399-402
Subacute Brachial Plexopathy due to Intraneural Epithelioid Hemangioma: A Case Report
Brachial plexopathy is a common consideration in the differential diagnosis of upper extremity sensory and motor deficits, and neoplasms signify one possible etiology of brachial plexopathy. Of the neoplastic brachial plexopathies, hemangiomas involving the brachial plexus are rare. Most reported cases describe extraneural brachial plexus hemangiomas that present as a palpable, tender neck mass associated with pain and sensory disturbance, with minimal motor deficits. Here we share the case of a 48 year-old man with intraneural epithelioid hemangioma of the brachial plexus who presented with prominent motor weakness and no palpable mass. The patient presented with subacute onset of left arm pain, numbness and progressive weakness. Neurologic exam revealed lower motor neuron signs and weakness spanning multiple nerve root and peripheral nerve distributions. Dedicated brachial plexus MRI showed two mass lesions involving the cords of the brachial plexus, with corresponding FDG-avidity on PET/CT. Biopsy revealed intraneural atypical epithelioid hemangioma. After nerve transfer surgery, he had moderate improvement in left arm strength. This case serves to: emphasize the importance of both clinical localization and dedicated brachial plexus imaging in the evaluation of brachial plexopathy; introduce to the literature a new clinical presentation of brachial plexus hemangiomas; encourage consideration of neoplastic brachial plexopathy even when faced with an illness script resembling Parsonage-Turner Syndrome, to avoid delays in diagnosis and treatment.
- 8 June 2022
- Published by SAGE Publications in The Neurohospitalist
- Vol. 12 (4) , 607-616
Glioblastoma in Patients With Multiple Sclerosis
Background: Although rare, the co-occurrence of multiple sclerosis (MS) and glioma poses unique challenges in terms of diagnosis and management for both neurologists and neuro-oncologists. Methods: Here we report on a single-center cohort of four patients with a diagnosis of multiple sclerosis who developed gliomas. Results: Our cohort reflects the epidemiology of glioma in terms of the relative frequency of IDH-wildtype and IDH-mutant cases. The patients in 3 out of the 4 cases presented did not develop their tumors in areas of pre-existing demyelinating lesions. Conclusions: We did not find evidence to support the hypothesis that chronic gliosis from demyelinating plaques may serve as a substrate for secondary induction of a glial neoplasm. In our Discussion, we provide recommendations for distinguishing neoplastic from demyelinating lesions, review the evidence for demyelination as a risk factor for gliomagenesis, and highlight important considerations for the concurrent management of glioma and MS.
- 8 June 2022
- Published by SAGE Publications in The Neurohospitalist
- Vol. 12 (4) , 607-616
Glioblastoma in Patients With Multiple Sclerosis
Background: Although rare, the co-occurrence of multiple sclerosis (MS) and glioma poses unique challenges in terms of diagnosis and management for both neurologists and neuro-oncologists. Methods: Here we report on a single-center cohort of four patients with a diagnosis of multiple sclerosis who developed gliomas. Results: Our cohort reflects the epidemiology of glioma in terms of the relative frequency of IDH-wildtype and IDH-mutant cases. The patients in 3 out of the 4 cases presented did not develop their tumors in areas of pre-existing demyelinating lesions. Conclusions: We did not find evidence to support the hypothesis that chronic gliosis from demyelinating plaques may serve as a substrate for secondary induction of a glial neoplasm. In our Discussion, we provide recommendations for distinguishing neoplastic from demyelinating lesions, review the evidence for demyelination as a risk factor for gliomagenesis, and highlight important considerations for the concurrent management of glioma and MS.